Publications by authors named "Emma C Scott"

Claim this Profile
I
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).
Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J Landau, Erica L Campagnaro, Emma C Scott

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Emma C Scott, Andrea C Baines, Yutao Gong, Rodney Moore, Gulsum E Pamuk

Nat Rev Drug Discov· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, R Angelo de Claro, Lola Fashoyin-Aje, Emma C Scott

JAMA Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Robert Cornell, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie Callander, Emma C Scott

Am J Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Kelly J Norsworthy, Flora Mulkey, Emma C Scott, Ashley F Ward, Donna Przepiorka

Clin Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Adam D Cohen, Noopur Raje, Jessica A Fowler, Khalid Mezzi, Emma C Scott

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Emma C Scott

Leukemia· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
Emma C Scott, Parameswaran Hari, Sathish Kumar, Raphael Fraser, Omar Davila

Biol Blood Marrow Transplant· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
Stephen B Heitner, Jessica Minnier, Aynun Naher, Ryan C Van Woerkom, Alexandra Ritts, Emma C Scott

Clin Lymphoma Myeloma Leuk· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M Mark, Emma C Scott

Haematologica· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.
Matthew J Pianko, Samuel A Funt, David B Page, Deepika Cattry, Emma C Scott

Leuk Lymphoma· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Mobile Element Locator Tool (MELT): population-scale mobile element discovery and biology.
Eugene J Gardner, Vincent K Lam, Daniel N Harris, Nelson T Chuang, Emma C Scott, Scott E Devine

Genome Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
Emma C Scott, Richard T Maziarz, Stephen E Spurgeon, Eva Medvedova, James Gajewski

Haematologica· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab.
Nathan D Gay, Craig Y Okada, Andy I Chen, Emma C Scott

Ther Adv Hematol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Somatic L1 Retrotransposition in Human Cancers.
Emma C Scott, Scott E Devine

Viruses· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.
Charles A Clark, Robert F Cornell, Emma C Scott, Jae Chung, Luciano J Costa

Am J Hematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Emma C Scott, Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang

Biol Blood Marrow Transplant· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Scott J Rodig

J Clin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer.
Emma C Scott, Eugene J Gardner, Ashiq Masood, Nelson T Chuang, Paula M Vertino, Scott E Devine

Genome Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Sagar Lonial, Brendan M Weiss, Saad Z Usmani, Seema Singhal, Ajai Chari, Emma C Scott

Lancet· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
Anita D'Souza, Angela Dispenzieri, Baldeep Wirk, Mei-Jie Zhang, Jiaxing Huang, Emma C Scott

J Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Matthew B Siegel, Selina Qiuying Liu, Monika A Davare, Stephen E Spurgeon, Marc M Loriaux, Emma C Scott

Oncotarget· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Scott J Rodig

N Engl J Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Emma C Scott, Stephen B Heitner, William Dibb, Gabrielle Meyers, Stephen D Smith

Clin Lymphoma Myeloma Leuk· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Dan T Vogl, Edward A Stadtmauer, Kay-See Tan, Daniel F Heitjan, Lisa E Davis, Emma C Scott

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis